Bo Liang (iVIEW Therapeutics)
Overview
Bo Liang is a prominent figure in the biopharmaceutical industry, known for his significant contributions to drug discovery, particularly in the ophthalmic therapeutics sector. He serves as the co-founder, Chairman, and CEO of iVIEW Therapeutics, a clinical-stage biotechnology company specializing in innovative eye treatments. Under Liang's leadership, iVIEW Therapeutics has focused on developing novel ophthalmic drugs that address unmet medical needs, including treatments for viral conjunctivitis and dry eye disease.
Recent Developments
- March 2024: The U.S. Food and Drug Administration (FDA) cleared iVIEW's Investigational New Drug (IND) application for its novel TRPM8 agonist, IVW-1001, designed to treat symptoms of dry eye disease. This marked a significant milestone in the company's strategic growth and innovation in the ophthalmic sector.
- May 2024: iVIEW Therapeutics announced the closure of a Series B funding round, securing $715,000 to fuel further development of its ophthalmic drug pipeline.
- September 2024: The company declared the completion of patient recruitment for its Phase 1/2 trial of IVW-1001, highlighting significant progress in clinical development. The clinical trial aims to evaluate the safety and efficacy of the drug, with results expected in early 2025.
- May 2024: IVIEW Therapeutics was featured for their development of an extended-release povidone iodine ophthalmic drop through an innovative in-situ gel formulation, targeting viral conjunctivitis and other ocular infections.
- November 2023: The company was recognized for holding 74 patents globally, with substantial research activity focused in the United States and China.
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Bo Liang |
| Born | Not publicly available |
| Nationality | Chinese |
| Occupation | Business Executive, Entrepreneur |
| Known For | Founding and leading IVIEW Therapeutics |
| Net Worth | Not publicly available |
| Education | BSc in Chemistry, Peking University; Ph.D. in Synthetic Organic Chemistry, University of Pennsylvania; MBA in Entrepreneurship and Finance, NYU Stern School of Business |
Early Life and Education
Bo Liang was born in China, where he pursued his undergraduate studies in chemistry at Peking University, graduating in 1992. Following his passion for chemical sciences, he moved to the United States and earned a Ph.D. in synthetic organic chemistry from the University of Pennsylvania in 2001. His quest for knowledge extended to business administration, leading him to attain an MBA with a focus on entrepreneurship and finance from the NYU Stern School of Business in 2008. These educational experiences were pivotal, providing him with a strong foundation in both scientific and business domains.
Career and Notable Achievements
Bo Liang's career trajectory is marked by his entrepreneurial spirit and innovative mindset:
- 2006: Co-founded CLS Pharmaceuticals in New York City, where he developed a combination drug for viral conjunctivitis, later licensed to Foresight Biotherapeutics.
- 2010: Founded Adesso Advanced Materials, focusing on recyclable resin technology, which saw commercial success in various industries.
- 2015: Established iVIEW Therapeutics, acquiring Deda Pharmaceuticals' intellectual property and expanding into novel drug delivery systems. iVIEW has since been at the forefront of ophthalmic therapeutic innovations.
- Publications and Patents: Liang has over 15 scientific publications and holds about 40 patents, underscoring his role as a prolific innovator in drug development.
Current Work and Impact
Bo Liang continues to lead iVIEW Therapeutics, steering the company towards breakthrough solutions in eye care. The firm is noted for its focus on extended-release drug formulations and innovative drug delivery technologies aimed at treating complex ocular diseases. Liang's work not only contributes significantly to medical advancements but also sets a benchmark for future developments in the pharmaceutical industry.
Conclusion
Bo Liang's journey from chemistry student to influential CEO reflects a strategic blend of scientific insight and business acumen. His leadership in iVIEW Therapeutics exemplifies the impact of innovative and passionate commitment to addressing unmet medical needs, particularly in ophthalmology. As the company advances its clinical trials and R&D efforts, Liang's contributions continue to influence the field positively, paving the way for new therapeutic breakthroughs and improved patient outcomes.